Elevance Health (ELV, Financial) announced it will disclose its financial performance for the first quarter of 2025 on April 22. According to the company's estimates, it projects a GAAP net income of $9.61 per diluted share for its shareholders. This figure incorporates roughly $2.36 per diluted share attributable to net unfavorable items. When these items are excluded, adjusted net income for shareholders is anticipated to be $11.97 per diluted share.
The company highlighted that its first-quarter outcomes align with predicted medical cost trends, particularly in its Medicare Advantage segment. Despite continued high costs in Medicare Advantage, Elevance Health's performance during the quarter met both its forecast and pricing expectations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 19 analysts, the average target price for Elevance Health Inc (ELV, Financial) is $493.87 with a high estimate of $585.00 and a low estimate of $428.00. The average target implies an upside of 15.32% from the current price of $428.26. More detailed estimate data can be found on the Elevance Health Inc (ELV) Forecast page.
Based on the consensus recommendation from 24 brokerage firms, Elevance Health Inc's (ELV, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Elevance Health Inc (ELV, Financial) in one year is $622.65, suggesting a upside of 45.39% from the current price of $428.26. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Elevance Health Inc (ELV) Summary page.
